Sanofi SAN-1.32%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

PARIS, Oct 17 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Thursday it was "surprised" by a renewed, higher offer for its consumer arm Opella from private equity firm PAI ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

After the fall of communism in 1989, Budapest emerged as one of the most enchanting destinations in central Europe, buzzing with spectacular landmarks, Michelin-starred restaurants, imposing Belle ...

Sanofi (NASDAQ:SNY) is close to a deal to sell its consumer health unit to private equity firm Clayton Dubilier & Rice for about €15 billion ($16.4 billion). A deal may be announced in the ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...